June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
PIEZO1 and PIEZO2 pathogenic variants identified in primary congenital glaucoma
Author Affiliations & Notes
  • Terri L Young
    Ophthalmology and Visual Sciences, University of Wisconsin System, Madison, Wisconsin, United States
  • Kristina Whisenhunt
    Ophthalmology and Visual Sciences, University of Wisconsin System, Madison, Wisconsin, United States
  • Sean Martin
    Ophthalmology and Visual Sciences, University of Wisconsin System, Madison, Wisconsin, United States
  • Stuart Tompson
    Ophthalmology and Visual Sciences, University of Wisconsin System, Madison, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Terri Young None; Kristina Whisenhunt None; Sean Martin None; Stuart Tompson None
  • Footnotes
    Support  Research to Prevent Blindness, Inc., University of Wisconsin Centennial Scholars Fund
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1127. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Terri L Young, Kristina Whisenhunt, Sean Martin, Stuart Tompson; PIEZO1 and PIEZO2 pathogenic variants identified in primary congenital glaucoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1127.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Primary congenital glaucoma (PCG) is a rare, leading cause of childhood blindness. Increased intraocular pressure (IOP) leads to globe and corneal enlargement, and retinal ganglion cell/optic nerve damage. To date, genetic studies have identified ~25% of PCG molecular etiology. We sought novel variants in glaucoma-implicated genes in a cohort of PCG families lacking mutations in known PCG genes (CYP1B1, LTBP2, TEK, and ANGPT1).

Methods : PCG patients referred to our study were consented, and medical histories and blood samples for DNA extraction were acquired. Probands were exome sequenced using the Sure Select Human All Exon v6 or Roche/Nimblegen SeqCap EZ v2 capture kits on an Illumina HiSeq 2000 platform. Variants that were synonymous, not in coding/splice site regions, or with an allele frequency >0.002 in the gnomAD database were removed using Golden Helix SVS software. Sanger sequencing confirmed the variants in probands and enabled co-segregation analyses in additional family members where available.

Results : Six families with PIEZO1 and/or PIEZO2 variants were identified by exome sequencing. For PIEZO1, two families were identified with compound heterozygous variants (p.Arg351Trp, p.Gln1519Pro; p.Met711Lys, p.Arg1404Trp) and another had a single heterozygous variant (p.Val499Ile). For PIEZO2, two families had a single heterozygous variant (p.Arg2731Gln, p.Val971Ile). Digenic inheritance of PIEZO1 (p.Pro913Ala) and PIEZO2(p.Glu1863Gly) variants were identified in a further family. All variants showed low frequencies in global and all ethnic populations (gnomAD), had CADD scores >20, and involved highly evolutionarily conserved residues, strongly suggesting pathogenicity.

Conclusions : Maintenance of IOP involves regulation of aqueous humor outflow via Schlemm's canal (SC), a unique hybrid vessel in the ocular anterior chamber angle with lymphatic and vascular properties. In mice, PIEZO1 and PIEZO2 proteins form mechanically activated ion channels expressed in lymphatic and vascular endothelial cells. PIEZO1 localizes to SC and is important for lymphatic valve formation in mice. Additionally, PIEZO2 is associated with regulation of aqueous outflow in mice. PIEZO1 expression in human trabecular meshwork cells has also been reported. These findings strongly suggest that PIEZO1 and PIEZO2 are involved in IOP regulation and that rare pathogenic variants are causal for PCG.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×